Metagenomi, Inc. (MGX) Price & Analysis

Compare

947 Followers

MGX Stock Chart & Stats

$1.76

-$0.33(-10.00%)

At close: Jan 08 4:00 PM EST

$1.76

-$0.33(-10.00%)

Day’s Range― - ―

52-Week Range$1.23 - $4.40

Previous CloseN/A

Volume382.73K

Average Volume (3M)883.52K

Market Cap

$66.08M

Enterprise Value-$107.01M

Total Cash (Recent Filing)$184.11M

Total Debt (Recent Filing)$41.66M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Apr 01, 2026

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding37,546,436

10 Day Avg. Volume1,405,864

30 Day Avg. Volume883,524

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)0.58

Price to Sales (P/S)2.58

P/FCF Ratio-1.20

Enterprise Value/Market Cap-1.62

Enterprise Value/Revenue-3.46

Enterprise Value/Gross Profit-15.11

Enterprise Value/Ebitda1.27

Forecast

1Y Price Target

$8.67

Price Target Upside392.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Competitive Edge In Drug DevelopmentNew P.C. dose-finding data in NHPs supports a competitive profile and a CTA/IND is slated for Q4:26, with continued progress on partnership efforts.

Valuation PotentialMGX trades significantly below cash, providing what is seen as plenty of upside potential with little near-term downside risk.

Workforce OptimizationMGX announced a pipeline re-prioritization and 25% workforce reduction which will put the focus on MGX's late-stage P.C. programs, led by MGX-001 for Heme A.

Bears Say

Operational RisksRisks include delays in advancing pipeline candidates into and through clinical assessment, as well as failure to generate favorable clinical data from ongoing programs.

Metagenomi, Inc. News

Metagenomi, Inc. Reports Q3 2025 Financial Results

Metagenomi, Inc. ( ($MGX) ) has released its Q3 earnings. Here is a breakdown of the information Metagenomi,...

1M ago

MGX

Metagenomi price target lowered to $7 from $11 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Metagenomi (MGX) to $7 from $11 and keeps...

1M ago

MGX

Metagenomi Announces Positive Preclinical Data for MGX-001

Metagenomi, Inc. ( ($MGX) ) just unveiled an update. On November 11, 2025, Metagenomi, Inc. announced positive preclinical...

1M ago

MGX

Metagenomi CEO Brian Thomas to transition out of role, Jian Irish to succeed

To support the next phase of development, Jian Irish, the company’s president and former COO, has been promoted...

1M ago

MGX

Metagenomi reports Q3 EPS (55c), consensus (53c)

Reports Q3 revenue $8.66M, consensus $7.92M. “In light of the encouraging preclinical MGX-001 hemophilia A results we reported...

1M ago

MGX

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

Metagenomi (MGX) reported new dose range finding data from the company’s MGX-001 hemophilia A program. The data demonstrated...

1M ago

MGX

Metagenomi reduces workforce by 25%

The company has strategically evolved its pipeline and discovery efforts to focus on the advancement of its leading...

1M ago

MGX

MGX Upcoming Earnings Report: What to Expect?

Metagenomi, Inc. (MGX) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

MGX

Video: This stock is dragging down the in vivo gene editing therapy space

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

2M ago

MGX

BEAM

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30...

2M ago

MGX

CRSP

Amazon’s (AMZN) Alexa Chips are More Powerful than Nvidia in Fighting Disease, Says Biotech

Amazon ($AMZN) has come out on top of rivals such as Nvidia ($NVDA) when it comes to utilizing...

2M ago

MGX

AMZN

Metagenomi Regains Control After Affini-T Agreement Termination

The latest update is out from Metagenomi, Inc. ( ($MGX) ). On September 29, 2025, Metagenomi, Inc. entered...

3M ago

MGX

AbCellera appoints Sarah Noonberg as Chief Medical Officer

AbCellera (ABCL) announced the appointment of Sarah Noonberg as Chief Medical Officer. Noonberg brings over two decades of...

3M ago

MGX

ABCL

Promising Prospects for Metagenomi, Inc.: Strategic Partnerships and Strong Financial Position Highlight Upside Potential

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Metagenomi, Inc.. The associated price target...

4M ago

MGX

MGX FAQ

What was Metagenomi, Inc.’s price range in the past 12 months?

Metagenomi, Inc. lowest stock price was $1.23 and its highest was $4.40 in the past 12 months.

What is Metagenomi, Inc.’s market cap?

Metagenomi, Inc.’s market cap is $66.08M.

When is Metagenomi, Inc.’s upcoming earnings report date?

Metagenomi, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 101 days.

How were Metagenomi, Inc.’s earnings last quarter?

Metagenomi, Inc. released its earnings results on Nov 11, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.584 by $0.034.

Is Metagenomi, Inc. overvalued?

According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Metagenomi, Inc. pay dividends?

Metagenomi, Inc. does not currently pay dividends.

What is Metagenomi, Inc.’s EPS estimate?

Metagenomi, Inc.’s EPS estimate is -0.61.

How many shares outstanding does Metagenomi, Inc. have?

Metagenomi, Inc. has 37,546,436 shares outstanding.

What happened to Metagenomi, Inc.’s price movement after its last earnings report?

Metagenomi, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.584. Following the earnings report the stock price went down -15.455%.

Which hedge fund is a major shareholder of Metagenomi, Inc.?

Currently, no hedge funds are holding shares in MGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Metagenomi, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-40.87%

Trailing 12-Months

Asset Growth

-29.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Metagenomi, Inc.

Metagenomi, Inc. (MGX) is a biotechnology company focused on developing innovative gene editing technologies and therapeutic solutions for genetic disorders. Operating primarily in the biotechnology and life sciences sectors, Metagenomi leverages its proprietary gene-editing platform to create precise, efficient, and safe gene therapies. The company's core products include gene-editing tools that enable targeted modifications to the genome, with applications across various therapeutic areas, including rare diseases, cancer, and infectious diseases.

Metagenomi, Inc. (MGX) Earnings & Revenues

Historic Earnings Reports

MGX Stock 12 Month Forecast

Average Price Target

$8.67

▲(392.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.4000000000000004,3.2,4,4.800000000000001,5.6,6.4,7.200000000000001,8,8.8,9.6,10.4,11.200000000000001,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.143846153846154,2.687692307692308,3.2315384615384617,3.7753846153846156,4.319230769230769,4.863076923076923,5.406923076923077,5.950769230769231,6.4946153846153845,7.038461538461538,7.582307692307692,8.126153846153846,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.0153846153846153,2.430769230769231,2.8461538461538463,3.2615384615384615,3.676923076923077,4.092307692307692,4.507692307692308,4.923076923076923,5.338461538461539,5.753846153846155,6.16923076923077,6.584615384615384,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >